Company news
Innovation Pharmaceuticals Inc. news in 2019
Innovation Pharmaceuticals Inc.'s news releases, calls and decks from 2019, newest first.
Innovation Pharmaceuticals: Patient Screening for Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program On Track for Early January
December 26, 2019
Innovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates
December 13, 2019
Innovation Pharmaceuticals Provides Update on Clinical Trials and Revenue Potential of Brilacidin in Inflammatory Bowel Diseases
December 10, 2019
Innovation Pharmaceuticals and FDA Agree to Waive Initial Pediatric Study Plan Requirement Regarding Brilacidin for the Prevention of Oral Mucositis
November 25, 2019
Innovation Pharmaceuticals: Oral Cancer on the Rise; Company Offers Perspectives on Opportunity of Brilacidin for the Prevention of Oral Mucositis
November 13, 2019
Innovation Pharmaceuticals Highlights Preclinical Data by Independent Cancer Researchers Supporting p53 Drug Candidate Kevetrin’s Potential in Treating Acute Myeloid Leukemia
October 28, 2019
Innovation Pharmaceuticals Partnering Provides Momentum For Inflammatory Bowel Disease Programs, Targeting a Substantial and Prized Market with a Large Unmet Patient Need
October 14, 2019
Innovation Pharmaceuticals Cites Recent Academic Literature Showing Host Defense Proteins at Cutting-Edge of Medicine for Multiple Diseases
October 8, 2019
Innovation Pharmaceuticals Clinical Trial of Oral Brilacidin in Ulcerative Colitis Program Expected to Commence in December; Top-Line Data in Q1 2020
October 3, 2019
Innovation Pharmaceuticals Engages Locust Walk, A Global Life Sciences Transaction Firm
September 30, 2019
Innovation Pharmaceuticals Announces Successful Formulation of Oral Brilacidin Tablets; Upcoming Clinical Trial to Target Delivery to the Colon
September 16, 2019
Innovation Pharmaceuticals Plans for Clinical Trial of Oral Brilacidin for Ulcerative Colitis Program in 4th Quarter 2019
September 10, 2019
Innovation Pharmaceuticals Provides Corporate Update Highlighting Clinical Pipeline Progress and Business Development Activities
July 29, 2019
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis
July 22, 2019
Innovation Pharmaceuticals Signs Agreement for Advanced Oral Tablet Technology in Treating Inflammatory Bowel Disease
June 6, 2019
Innovation Pharmaceuticals to Attend 2019 BIO International Convention, June 3-6
May 29, 2019
Innovation Pharmaceuticals At Digestive Disease Week Conference, Nears Selecting Drug Formulation Company to Prepare Oral Brilacidin for Targeted Delivery in Ulcerative Colitis
May 21, 2019
Innovation Pharmaceuticals Announces Non-Binding Term Sheet Signed with Global Pharmaceutical Company to Develop and Commercialize Brilacidin for the Treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis
May 16, 2019
Innovation Pharmaceuticals Receives FDA End-of-Phase 2 Meeting Minutes
May 1, 2019
Innovation Pharmaceuticals - "JAMA" Article Reinforces Need for Novel Oral Mucositis Treatments in Supportive Cancer Care; Company progresses through first stage of review by European Medicines Agency (EMA) regarding Scientific Advice for planne
April 23, 2019
Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies
April 16, 2019
Innovation Pharmaceuticals Reports Enhancements in Manufacture of Brilacidin Phase 3 Drug Supply
April 9, 2019
Innovation Pharmaceuticals European Subsidiary, IPIX Pharma Ltd., Granted Meeting with European Medicines Agency (EMA) to Discuss International Phase 3 Brilacidin Oral Mucositis Program
March 27, 2019
Innovation Pharmaceuticals Requesting European Medicines Agency (EMA) Input for International Phase 3 Brilacidin Oral Mucositis Program
March 15, 2019
Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline
February 26, 2019
Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis
February 19, 2019
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
February 10, 2019
Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX
January 31, 2019
Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease
January 22, 2019
Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease
January 14, 2019
Published Studies Confirm Cisplatin Remains Preferred Chemotherapy Component in Head and Neck Cancer Treatment; Innovation Pharmaceuticals on Target with Clinical Trials of Brilacidin for Preventing Severe Oral Mucositis
January 8, 2019
Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate
January 2, 2019